Vaccines-2013 - OMICS Group

Track 33: Novel Approaches in Design of Cellular and Molecular-Based VaccinesSession ChairNikolai PetrovskyFlinders University, AustraliaSession Co-ChairRajesh Kumar SharmaUniversity of Louisville, USASession IntroductionTitle: Applications of the Vaccine Ontology (VO) in vaccine data integration and computer-assistedautomated reasoningYongqun He, University of Michigan Medical School, USATitle: Rational design of Synthetic Vaccine Particles (SVP) for therapeutic treatment of chronicdiseasesTakashi Kei Kishimoto, Selecta Biociences, USATitle: Efficacy of a mixture of synthetic peptides overlapping the conserved CBD1 epitope in gp41 ofHIV-1 to protect against SHIV162P3 rectal challenge in cynomolgus macaquesAra Hovanessian, CNRS-Université Paris Descartes, FranceTitle: Protection against influenza from RNActive® technologyBenjamin Petsch, CureVac GmbH, GermanyTitle: A novel form of 4-1BB ligand as a potent and safe adjuvant for development of therapeuticcancer vaccinesRajesh Kumar Sharma, University of Louisville, USATitle: Correct L1 initiation codon generates immunologically reactive virus-like particles of a novellaboratory mouse papillomavirus (MusPV)A. Bennett Jenson, University of Louisville, USATitle: The T-body approach combining antibody specificity with T cell activity for adoptivevaccination of cancerZelig Eshhar, The Weizmann Institute of Science, IsraelTitle: Novel non-pyrogenic hydrophobized norAbuMDP and norAbuGMDP analogues forconstruction of proteoliposome vaccinesMilan Raska, Palacky University, Czech RepublicTitle: The pharmacodynamic study and safety evaluation on tuberculosis DNA vaccinesXueqiong Wu, Institute for Tuberculosis Research, ChinaTitle: Nanoparticles: The next generation delivery vehicle for DNA vaccinesMuhammad Ali Shah, Southeast University, ChinaDay 2 July 30, 2013Page 49